329 related articles for article (PubMed ID: 20719220)
1. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.
Brotherton JM; Kaldor JM; Garland SM
Sex Health; 2010 Sep; 7(3):310-9. PubMed ID: 20719220
[TBL] [Abstract][Full Text] [Related]
2. Cytology and cervical cancer surveillance in an era of human papillomavirus vaccination.
Budd AC; Sturrock CJ
Sex Health; 2010 Sep; 7(3):328-34. PubMed ID: 20719223
[TBL] [Abstract][Full Text] [Related]
3. Cancers attributable to human papillomavirus infection.
Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
[TBL] [Abstract][Full Text] [Related]
4. Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.
Pitts MK; Heywood W; Ryall R; Smith AM; Shelley JM; Richters J; Simpson JM
Sex Health; 2010 Sep; 7(3):299-303. PubMed ID: 20719218
[TBL] [Abstract][Full Text] [Related]
5. What can surveillance of genital warts tell us?
Fairley CK; Donovan B
Sex Health; 2010 Sep; 7(3):325-7. PubMed ID: 20719222
[TBL] [Abstract][Full Text] [Related]
6. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
Drolet M; Bénard É; Pérez N; Brisson M;
Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
[TBL] [Abstract][Full Text] [Related]
7. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
8. Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine.
Brotherton JM; Fairley CK; Garland SM; Gertig D; Saville M
Sex Health; 2010 Sep; 7(3):397-8. PubMed ID: 21058499
[No Abstract] [Full Text] [Related]
9. National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program.
Brotherton JM; Leask J; Jackson C; McCaffery K; Trevena LJ
Sex Health; 2010 Sep; 7(3):291-8. PubMed ID: 20719217
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys.
Rob F; Tachezy R; Pichlík T; Rob L; Kružicová Z; Hamšíková E; Šmahelová J; Hercogová J
Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27723194
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
12. For debate: that Australia should consider changing to the bivalent vaccine.
Stern PL
Sex Health; 2010 Sep; 7(3):238-41. PubMed ID: 21058497
[No Abstract] [Full Text] [Related]
13. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
14. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
15. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
Van de Velde N; Boily MC; Drolet M; Franco EL; Mayrand MH; Kliewer EV; Coutlée F; Laprise JF; Malagón T; Brisson M
J Natl Cancer Inst; 2012 Nov; 104(22):1712-23. PubMed ID: 23104323
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer vaccine development.
Frazer IH
Sex Health; 2010 Sep; 7(3):230-4. PubMed ID: 20719210
[TBL] [Abstract][Full Text] [Related]
17. [Diseases caused by human papilloma viruses].
Zollner U; Schwarz TF
Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
[TBL] [Abstract][Full Text] [Related]
18. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
19. The HPV vaccine controversy.
Intlekofer KA; Cunningham MJ; Caplan AL
Virtual Mentor; 2012 Jan; 14(1):39-49. PubMed ID: 23116916
[No Abstract] [Full Text] [Related]
20. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia.
Gertig DM; Brotherton JM; Saville M
Sex Health; 2011 Jun; 8(2):171-8. PubMed ID: 21592430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
